The following information is from Children’s Health Defense.
Advisers to the FDA recently met to discuss the future of respiratory syncytial virus (RSV) vaccines for children. This followed Moderna’s forced halt of its mRNA RSV vaccine trials after alarming data showed higher rates of severe RSV in vaccinated infants compared to those given a placebo. Clinical trial data revealed 12.5% of vaccinated children developed severe RSV disease, compared to just 5% in the placebo group.
These outcomes raised alarms due to past experiences with RSV vaccines. In the 1960s, trials of a formalin-inactivated RSV vaccine led to vaccine-associated enhanced respiratory disease (VAERD), where vaccination worsened illness instead of preventing it. That trial resulted in two toddler deaths and hospitalization for 80% of the vaccinated participants. Despite decades of research, the risks tied to VAERD remain unresolved.
FDA advisers emphasized the “unmet need” for pediatric RSV vaccines, framing RSV as a leading cause of infant hospitalizations in the US annually. Vaccine makers, spurred by a projected $13.59 billion global RSV vaccine market by 2030, are developing 26 RSV vaccines or monoclonal antibodies for all age groups.
An FDA representative said the Centers for Disease Control and Prevention (CDC) estimates that RSV causes 100-200 infant deaths annually. However, internist Dr. Meryl Nass argued these numbers are overstated. Citing a CDC study analyzing RSV deaths in infants from 2005 to 2016, Nass highlighted that there were 314 deaths in children under age 1 during that period, averaging 25 per year. Only 17 of those deaths listed RSV as the direct cause, raising questions about the urgency for widespread vaccination.
The FDA explored the potential for sequential administration of RSV monoclonal antibodies and vaccines for infants and toddlers. This approach would begin with monoclonal antibodies or maternal vaccination to provide “passive immunity” — ready-made antibodies to fight RSV. Later, a two- or three-shot course of RSV vaccines would aim to develop “active immunity,” enabling the child’s own immune system to combat the virus in subsequent seasons.
While committee members saw potential in sequential administration, they acknowledged insufficient safety data, fueling concerns that industry profits are being prioritized over child safety.
For more details, rand to watch the full FDA advisory meeting click here.

I stopped stopped getting sick when I stopped taking vaccines. That was about 20 years ago.
Would you buy any product or service in America, of any type or use, that is immune from liability?
“…a projected $13.59 billion global RSV vaccine market by 2030.” That’s the whole story.
Why aren’t these people in jail?
This same ‘vaccine enhancement’ also known as ‘antibody dependent enhancement’ was noted with the ‘covid’ mRNA injections. During the trials, an article published on NIH’s suggested all people getting these injections get a waiver mentioning it. No one did, of course.
Trump’s DoGE initiative needs to eliminate all non-federal workers at FDA as well as any federal workers that came from the pharmaceutical industry. That may mean that FDA will have no employees which will make us healthier again.
Federal employees that sell out the people they are supposed to serve should be treated as traitors and hung. They are responsible for countless deaths and injuries.
The patent holder of the mRNA technology asserted that mRNA products are not vaccines, they are gene therapies. What is being pushed here is a new manufacturing method that skirts the review and approval process that brings drugs to market. The testing process is lengthy and exorbitantly expensive. It is a new “platform vs payload” manufacturing process whereby a new “payload,” i.e. the stuff that gets injected, can be produced by a change in a software instruction that results in production of a different messenger RNA instruction that gets injected into our bodies. They are NOT injecting weakened or dead virus into our bodies, as has been done in the past. Once the “platform” gains wide acceptance, the “testing” of this new manufacturing technology ends, and with it the expense associated with bringing new drugs to market. A whole new universe of boutique gene therapies can be manufactured and not have to be tested. The “platform”, i.e. the MANUFACTURING PROCESS, will be accepted as “safe and effective”. To market this to parents with infants is unforgivable. This kind of human experimentation was supposed to have been outlawed by the Nuremberg Code. This is the result of unethical, unsupervised “experts” who are blithely listened to without question.
that rsv /mmr combo shot almost killed my 6 month old grandson and gave him kawasaki disease.